Source-grounded facts extracted from Foghorn Therapeutics Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Foghorn Therapeutics Inc. reported financial results for the quarter ended March 31, 2026.
“On May 7, 2026, Foghorn Therapeutics Inc. (the “Company”) issued a press release announcing certain of the Company’s financial results for the quarter ended March 31, 2026.”
Neil J. Gallagher was appointed as Director at Foghorn Therapeutics Inc..
“appointed Neil J. Gallagher, M.D., Ph.D. to the Board, effective May 1, 2025.”
Stuart Duty was appointed as Director at Foghorn Therapeutics Inc..
“appointed Stuart Duty to the Board, effective May 1, 2025.”
Foghorn Therapeutics Inc. received a nasdaq deficiency notice notice regarding audit committee.
“January 23, 2025, Foghorn Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Stock Market LLC (the “Nasdaq”) notifying the Company that it no longer complies with Nasdaq’s audit committee”
Foghorn Therapeutics Inc. reported financial results for the quarter ended March 31, 2024.
“On May 6, 2024, Foghorn Therapeutics Inc. (the “Company”) issued a press release announcing certain of the Company’s financial results for the quarter ended March 31, 2024.”
Stephen DiPalma departed as Interim Chief Financial Officer at Foghorn Therapeutics Inc..
“In connection with Mr. Humer’s appointment, Stephen DiPalma, the Company’s Interim Chief Financial Officer, principal financial officer and principal accounting officer, will cease to serve in such roles.”
Kristian F. Humer was appointed as Chief Financial Officer at Foghorn Therapeutics Inc..
“On April 16, 2024, Foghorn Therapeutics Inc. (the “Company”) announced that Kristian F. Humer had been appointed to serve as the Company’s Chief Financial Officer, effective immediately.”
Foghorn Therapeutics Inc. reported the year ended December 31, 2023 results: revenue $34.2 million.
“three discovery programs using Foghorn’s proprietary Gene Traffic Control platform. Full Year 2023 Financial Highlights • Collaboration Revenues . Collaboration revenues were $34.2 million for the year ended December 31, 2023, compared to $19.2 million for the year ended December 31, 2022. The increase year-over-year was primarily driven by revenue recognized under”
Stephen J. DiPalma was appointed as Treasurer and interim Chief Financial Officer at Foghorn Therapeutics Inc..
“On January 16, 2024, the Board of Directors of Foghorn Therapeutics Inc. (the “Company”) appointed Stephen J. DiPalma as Treasurer and interim Chief Financial Officer (“CFO”), effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.